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Complete nucleotide sequence, origin of isoform and functional
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Hepsin, a type-II membrane-associated serine protease, has been implicated in cell growth and developement as well
as possible initiation of blood coagulation. Here, we report on the complete nucleotide sequence, functional
characterization of key structural features and the promoter of the mouse hepsin gene. The gene has a size of
<17 kb, and is composed of 12, 13, or 14 exons depending on alternative intron splicings ± one in the 5 0-UTR and
the other two in the second intron. The latter two, which occur in approximately half of the hepsin transcripts,
generate a hepsin mRNA species with an extra exon, which is responsible for producing a hepsin isoform with a
unique 20-residue sequence inserted in the cytoplasmic portion of hepsin. Most hepsin transcripts have the 5 0-UTR
intron spliced, and its splicing can occur independently of the other alternative splicings. The transcriptional
initiation site was determined to be 636 bp upstream of the first ATG site in a cytidine-rich region. The 5 0-flanking
region of hepsin up to nucleotide 274 showed a substantial promoter activity in HepG2 cells, with its expression
activity sevenfold higher in the presence of the 5 0-UTR intron sequence in comparison to that without the intron
sequence. The basal promoter region contains potential binding sites for several transcription factors including SP1,
AP2, C/EBP, LF-A1, and E box, which may be responsible for ubiquitous, but liver- and kidney-preferred tissue
expression of the hepsin gene.
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Hepsin, a serine protease, was originally found as cDNA clones
isolated from a human liver cDNA library [1,2]. Subsequent
studies determined that hepsin is a type-II membrane-associated
protease of <50 kDa with its carboxyl-terminal-half proteolytic
subunit at the cell surface [2±4]. Hepsin is also present in
subcellular organelle fractions such as nucleus and mitochondria
[3]. Recently, the rat hepsin cDNA has been determined [5]. Rat
hepsin is composed of 416 amino-acid residues, one residue
shorter than human hepsin. Hepsin has been implicated in cell
growth [6], development [7], and more recently in cell-surface
initiation of blood coagulation [8] as well as possible prostate
cancer cell function [9]. These observations strongly suggest
that hepsin may play many important roles. However, homo-
logous recombination-based gene inactivation of mouse hepsin
showed that deficiency of hepsin does not result in any severe
abnormal phenotypes, other than a significant increase in the
level of alkaline phosphatase [10]. Unexpectedly, an observed
mild hepsin-deficiency phenotype in mice may be due to the
possible presence of one or more complementing systems. This
situation appears similar to other reported cases where gene
inactivation in mice does not necessarily agree with the
phenotypic changes predicted or observed with the deficiency
of such genes in humans [11±13]. As no human hepsin
deficiency is known of to date, it is difficult at the present
time to explain the phenotype observed in hepsin knockout
animals.
In the present study, we describe the complete nucleotide
structure, characteristics of key structural elements, characteri-
zation of alternative splicings and functional analyses of the
promoter region of the mouse hepsin gene.
EXPERIMENTAL PROCEDURES
Materials
A l FIXII mouse genomic library constructed with liver DNA
from mouse (strain 129) was purchased from Stratagene.
Restriction enzymes, calf intestinal alkaline phosphatase, and
T4 DNA ligase were purchased from New England Biolabs. T4
polynucleotide kinase was obtained from United States
Biochemical. Qiagen plasmid kit was purchased from Qiagen
Inc. Taq polymerase, SuperScriptTMII Reverse Transcriptase,
SuperScript One-StepTM reverse transcription-polymerase chain
reaction (RT-PCR) system, RNase H, pUC18, pBluescript,
agarose, Dulbecco's modified Eagle's medium (DMEM), fetal
bovine serum, and sheared herring sperm DNA were purchased
from GIBCO Life Technologies. DNase I and FugeneTM 6
transfection reagent were obtained from Beohringer Mannheim.
b-Galactosidase expression plasmid vector (pCH110) was
obtained from Pharmacia P-L Biochemical. Vitamin K (Aqua-
Mephyton) was from Merck Sharp & Dohme. TA cloning kit
was from Invitrogen. Radioactive nucleotides ([a-32P]dCTP,
[g-32P]ATP, and [a-33P]dNTP), Megaprime labeling kit, and
Rapid-Hyb hybridization solution were obtained from Amer-
sham Inc. Maximum strength Nytran filters were from
Schleicher & Schell Co. Synthetic oligonucleotides were
prepared by using an automated synthesizer (Applied Bio-
systems, Model 394) at the Molecular Biology Core Facility of
this campus. ELISA equipment was from Bio-Rad. Mouse
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monoclonal anti-(human factor IX) (hFIX), AHIX5041, was
purchased from Hematologic Diagnosis Inc., and polyclonal
anti-hFIX IgG±peroxidase conjugate was purchased from
Enzyme Research Laboratories Inc. Pooled normal human
plasma was obtained from George King Bio-Medical Inc.
Top10 F 0 cells and X-ray films (X-Omat AR) were purchased
from Invitrogen Corp. and Kodak, respectively. All other
chemicals used were of analytical grade specified for bio-
chemical and molecular biology use.
Screening of the lFIXII genomic library
Screening of l phage genomic library was carried out by the
standard method [14]. Briefly, the library was propagated in
Escherichia coli XL-1-Blue MRA, and <500 000 independent
phages were plated at a density of 5.0  104 phages per
150-mm plate. Phage particles transferred to nylon filters were
then screened with the human hepsin cDNA [1] labeled with
32P to a specific activity of 1.0  109 c.p.m.´mg21 by
employing the random priming method using a Megaprime kit
(Amersham). Positive clones identified were plaque-purified and
amplified on plates to obtain high-titer stocks. Large-scale
preparations of recombinant phages were then carried out by the
liquid culture method [15]. Phage clones containing the 5 0-end
region of the mouse hepsin gene were obtained by screening the
genomic library with a genomic DNA fragment (667 bp in size)
corresponding to the most 5 0-end region of the insert of a phage
clone mHepl61 by PCR.
DNA sequence analysis
Phage DNAs were digested with NotI, and electrophoresed on
an 0.6% agarose gel. The insert DNAs were then recovered by
utilizing GenecleanwII (BIO 101 Inc.), subcloned into the
pBluescript vector at the NotI site, and used for subsequent
restriction mapping and sequencing. Southern blot analysis of
restriction fragments was carried out with either ApaI/StyI
(257 bp) or Bgl II/ApaI (422 bp), which represents the 5 0- or
3 0-distal portions of the human hepsin cDNA sequence,
respectively [1]. Selected restriction fragments of the inserts
were subcloned into pUC18 and subjected to sequencing using
Thermal Sequenase radiolabeled terminator cycle sequencing kit
(Amersham). All sequences were analyzed two (once for each
strand) or more times to eliminate inadvertent errors with M13
universal primers and hepsin-specific oligonucleotide primers.
DNA sequences were stored and analyzed by the dnasis
program (Hitachi SK) and the GCG program in the vax
computer at the General Clinical Research Center of this
campus.
Primer extension analysis
Primer extension analysis was carried out as previously
described, with minor modifications [16]. An oligonucleotide
primer (19 nucleotides in length), designed to the nucleotide
sequence +77 to +95, was labeled with 32P to a specific activity
of 5.8  108 c.p.m.´mg21 by employing T4 polynucleotide
kinase and [g-32P]ATP. An aliquot of the probe
(2.0  106 c.p.m.) was mixed with 10 mg of mouse liver total
RNA. A total RNA sample treated with RNase A and a total
RNA sample without treatment were included as controls.
Sequencing ladders generated from the DNA fragment, which
contains the corresponding region as the template, were used as
size markers.
PCR analysis of alternative splicings
RT-PCR of mouse liver hepsin mRNA were performed with
SuperScript One-StepTM RT-PCR system (GIBCO Life Tech-
nologies) to analyze alternative splicings. Aliquots of total liver
RNA (1 mg) isolated from C57B/6 mice were reverse tran-
scribed at 50 8C for 30 min with primer f (5 0-ATTGGAGCGT-
GAGGAGCACAGTAG-3 0) (Fig. 4A). This primer corresponds
to a sequence in exon 6 (nucleotides +11 460 to +11 483) of the
mouse hepsin gene. Specific amplification of the regions
containing the entire region of alternative splicings was then
performed with primer a (5 0-CACCCTTGCCTTCCGGG-
CTGTC-3 0, nucleotides +87 to +108 in exon 1) and primer f.
Then, PCR was carried out as follows: initial incubation at 94 8C
for 2 min, followed by 35 cycles of 94 8C for 30 s, 58 8C for
30 s, and 72 8C for 1 min, finishing with a 10-min extension at
72 8C. A total RNA sample treated with RNase A was included
as a negative control. The resulting PCR products, a mixture of
fragments of different size ranging from 300 to 900 bp, were
gel-purified and used as the template for subsequent PCR
with the common 5 0- primer b (5 0-TTCCGGGCTGTCCGC-
TGCTG-3 0, nucleotides +97 to +116 in exon 1) and, either
primer d (5 0-TGCAGTCCGGCCACCCTCCTTC-3 0, sequence
spanning the junction of exon 2 and exon 4, nucleotides +642 to
+649 and nucleotides +6067 to +6080, respectively) or primer e
(5 0-TGCAGTCCGGCCACCCTTTCCA-3 0, sequence spanning
the junction of exon 3 and exon 4, nucleotides +4552 to +4559
and nucleotides +6067 to +6080, respectively). PCR ream-
plification was also performed with primer c (5 0-CAGG-
GTCGGCTGCTCCCTG-3 0, nucleotides +484 to +501 in
intron 1) and either primer d, e, or f. PCR products were
seperated by 2% agarose gel electrophoresis. DNA fragments
produced were then cloned into a pCR2.1 vector (TA cloning
kit, Invitrogen). Positive identification of the cloned fragments
was performed by DNA sequencing analysis.
Cell culture
HepG2 cells, a human hepatoma cell line [17±19], were used for
transient expression assay as described previously [20]. Cells
were grown and maintained in DMEM supplemented with 10%
fetal bovine serum and antibiotics (penicillin and streptomycin)
at 37 8C under 5% CO2 in a humidified incubator. Fetal bovine
serum used in HepG2 cell culture for assaying factor IX activity
was pretreated with barium sulfate as previously described [21].
Construction of expression vectors
hFIX expression vector p-416FIXm1, which has been previously
described [20], was used as the starting vector for constructing
two expression vectors containing the hepsin promoter. The
hepsin promoter region (nucleotides 2274 to +59) was
generated by PCR with the hepsin genomic DNA as the
templete, using the 5 0- and 3 0-primers with SphI and NheI
linkers, respectively. The SphI/NheI fragment generated (333 bp
in size) was inserted into p-416FIXm1 at SphI/NheI sites
replacing hFIX promoter sequence (nucleotides 2416 to +22),
thus generating p-274HSN/FIXm1, which has no 5 0-UTR
intron. p-274HSNIn/FIXm1 was generated by inserting a
PCR-amplified hepsin fragment (890 bp in size, spanning
nucleotides 2274 to +616), which has the 5 0-UTR intron
sequence, into p-416FIXm1 in a similar manner as described for
the construction of p-274HSN/FIXm1. All the PCR-amplified
regions and ligation sites of the expression vectors were
sequenced to verify the correct sequences. Large-scale
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preparations of p-274HSN/FIXm1 and p-274HSNIn/FIXm1
were performed with Qiagen plasmid kit (Qiagen Inc.), and used
for transient expression assays [22]. These expression vectors
with the well-defined factor IX reporter gene allow efficient
evaluation of promoter strength simply by determining the
secreted factor IX.
Transient factor IX expression assays
Transient expression assays of p-274HSN/FIXm1 and
p-274HSNIn/FIXm1 were performed as previously
described [20] using HepG2 cells and FugeneTM 6 Transfection
Reagent (Boehringer Mannheim). hFIX produced into the
culture medium was quantified by ELISA [20]. HepG2 cells
(60±70% confluency in 6-cm dishes) were cotransfected with a
mixture of 8 mg of test-expression vectors and 0.8 mg of
pCH110 (internal control for transfection efficiency). Sheared
herring sperm DNA and p-416FIXm1 were used for transient
assays as the mock and positive controls, respectively. Expres-
sion values obtained for the herring sperm DNA mock control
were subtracted from those of the factor IX expression vectors.
Unless otherwise indicated, all expression vectors were assayed
in duplicate in four independent experiments, and averages of
the results are presented.
RESULTS
Isolation and sequencing of the mouse hepsin gene
Two positive phage clones, designated as mHepl61 and
mHepl11, were initially isolated from the mouse liver genomic
DNA library in lFIXII (5  105 independent phage clones)
(Fig. 1A). mHepl61 contained most of the middle portion, and
mHepl11 contained the 3 0-half of the gene. By screening
<3  105 independent phages of the same library with the
5 0-portion of the insert of mHepl61 as the screening probe,
the third clone mHepl3, which contains the 5 0-end region, was
obtained. Inserts of these clones were subjected to sequencing
analysis.
The complete contiguous nucleotide sequence for the mouse
hepsin gene, which spans <17 kb, is shown in Fig. 2. The gene
consists of 12±14 exons (1±14) depending on three alternative
splicings, which are responsible for generating exon 2 and/or 3.
Possible exon/intron organization combinations are shown in
Fig. 1B. Exon sequences accounted for 11% of the gene length.
The transcription initiation site determined by primer extension
analysis was at 636 bp 5 0-upstream of the first methionine codon
in the 5 0-UTR [23] and was designated nucleotide +1 (Fig. 2).
Exons size ranges from 41 bp (exon 8) to 349 bp (exon 14), and
that of intron from 76 bp (intron 5) to 5417 bp (intron 2). Intron
splicing junctions conform to the GT-AG rule [24,25]. The first
intron located in the 5 0-UTR is subjected to alternative splicing
(Fig. 1B, 1a and 1b). Exon 4 encoded most of the transmem-
brane domain. Two alternative splicings, which might take place
in the second intron (Fig. 1B, 1a), could generate an extra exon
(exon 3) encoding an in-frame sequence of 20 amino-acids,
DEEPGAHRGGSTCSRPQPGK (Fig. 2), which was found in
some, but not all, mouse cDNA clone [7]. Exon 5 encodes the
C-terminal end region (5 amino-acid sequence) of the trans-
membrane domain and a stretch of 9 amino acids. Exons 6±8
encode the spacer region between the membrane spanning
hydrophobic sequence and catalytic subunit. The serine protease
catalytic subunit consisted of 255 amino-acid residues is
encoded by six exons (exon 9±14). If the exon/intron
organization is that of Fig. 1B, 2a, the predicted size of hepsin
mRNA is 1806 bases, in agreement with one of the two distinct
mRNA species (<1.8 kb and 1.9 kb) observed in Northern
blot analysis [7]. If no alternative splicing takes place either
in the 5 0-UTR or in the second intron generating exon 3 as
shown in Fig. 1B, 1b, the 1.9-kb mRNA species may be
generated.
Several different repetitive sequences were found in the
introns and flanking regions (Fig. 2). B1 elements of the B-type
repeats [26±29] were found in intron 2 (nucleotides +5225 to
+5357 in 5 0- to 3 0- orientation) and intron 4 (nucleotides
+10 695 to +10 798 in 3 0- to 5 0- orientation), while B2
elements were present in intron 9 (nucleotides +13 495 to
+13 679 in 5 0- to 3 0- orientation, and nucleotides +14 507 to
+14 699 in 3 0- to 5 0- orientation). A polypurine tract of the
structure (AGGG)13 was located in intron 4 (nucleotides
+8406 to +8457). Five and a half tandem repeats of 30-bp
Fig. 1. Exon/intron organization of the mouse hepsin gene (A) and
multiple forms of mRNA (B). In panel A, three phage genomic clones,
mHepl11, mHepl61, and mHepl3, are shown in relation to the schematic
structure of the mouse hepsin gene. Exons are shown by vertical bars. The
size scale is in kilobases. In panel B, relevant portions (exons 1±4) of
multiple mRNA forms of hepsin generated by alternative splicings are
shown. Exons are represented by boxes with numbers and spliced introns are
shown by thin lines. Exon 1 0 (nucleotides + 1 to +649) is generated by no
splicing of the first intron (intron 1), and exon 3 (nucleotides +4500 to
+4559) is generated by alternative splicings in the second intron.
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Alu-like type III repetitive sequence [30] were also present in
intron 4 (nucleotides +8935 to +9214). This stretch of repeat
sequences has a 90% similarity to that found in murine
urokinase-type plasminogen activator receptor gene [31].
These repeats may be able to form stem-loop structures.
In addition to these, a stretch of dinucleotide repeats
(CA)7TA(CA)13 and (TG)23(CG)9, which are capable of
forming left-handed Z-DNA structure [32±34], were found
in intron 9 (nucleotides +13 423 to +16 464) and in the
3 0-flanking region of the gene (nucleotides +16 757 to
+16 820), respectively.
Nine nucleotide sequence differences were found between the
coding sequence reported in the present study and that of the
mouse cDNA recently reported by Vu et al. [7]. These
differences included those at nucleotides 11 423 (A), 11 429
(A), 11 435 (G), 11 450 (T), 11 622 (G), 12 211 (T), 12 506
(T), 12 531 (T), and 15 732 (C). Bases in parentheses were
previously reported by Vu et al. [7]. The difference at nucleotide
11 435 causes an amino-acid change from Leu65 [7] to Phe65 in
the present study. These differences may be due to sequencing
errors in the reported cDNA or to mouse strain-dependent
polymorphisms. The predicted amino acid sequence of the
mouse hepsin showed an overall similarity of 88% or 97% with
those of human [1] and rat hepsin [5], respectively.
Transcriptional initiation site
The major transcription initiation site for the mouse hepsin gene
was mapped to C at the position, 636 bp 5 0-upstream to the first
Met residue codon (Fig. 3), and was defined as nucleotide +1 in
the numbering system (Fig. 2). No such signals were observed
in control lanes containing either a total RNA sample treated
with RNase A or a total RNA alone (Fig. 3, lanes 1 and 2).
Characterization of alternative splicings
Comparison of the mouse hepsin genomic sequence with those
of human [1] and mouse [7] hepsin cDNAs suggested possible
alternative splicings, which were responsible for generating
multiple cDNA forms. This possibility was tested by a
combination of RT-PCR and subsequent PCR analyses using
total mouse liver RNA and pairs of specific primers (Fig. 4A).
RT-PCR amplification with a combination of primer a and
primer f yielded two bands of 462 and 402 bp, and an
unaccounted band of <490 bp (Fig. 4B, lane 2). The first two
bands corresponded to the products predicted for hepsin cDNA
species with or without exon 3 (Figs 1B, 1a and 2a),
respectively. This was further confirmed by DNA sequencing.
Control RT-PCR performed with RNA samples treated with
Fig. 2. The complete contiguous nucleotide sequence and encoded amino acid sequences of the mouse hepsin gene. The nucleotide numbering system is
based on the definition of the transcription initiation site (C) as nucleotide +1. The 5 0 upstream of nucleotide +1 is designated with reverse negative numbers. The
site of polyadenylation (nucleotide +16 300) is indicated by an asterisk. Nucleotide sequences of exons are shown with capital letters, whereas those of introns
and 5 0- and 3 0-flanking regions are represented with small letters. The poly(A) signal sequence of AATAAA is boxed. The deduced amino-acid sequence is
shown above the corresponding nucleotide sequences. Amino acid numberings in parentheses are of the isoform (Figs 1B, 1a) with the extra amino acid sequence
generated by alternative splicings in the second intron. Repetitive sequences including B1, B2, and Alu-like type III elements are underlined, while the sites of
putative regulatory elements in the 5 0-flanking region are shown by double underlines. The transmembrane domain of the amino acid sequence is indicated by
dotted line. The putative zymogen activation site and active site triad forming residues are marked with an arrow and open circles, respectively.
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RNase A and the same primer set did not result in amplification
products, confirming the high specificity of RT-PCR used
(Fig. 4B, lane 5). We further confirmed the existence of
alternative splicings, generating 1a and 2a, by subsequent PCR
using the first RT-PCR products as a template and primer b in
combination with splice variant-specific primers d and e,
respectively. The resulting PCR products of 105 and 165 bp
(Fig. 4B, lanes 6 and 7) corresponded to hepsin isoforms 2a and
1a, respectively. 1a and 2a corresponded to hepsin isoforms with
and without a 20 amino acid stretch of extra-sequence in the
cytosolic side of hepsin, respectively. No RT-PCR amplification
products with expected sizes of 793 and 853 bp for hepsin
isoforms 2b and 1b, respectively, which should correspond to
hepsin mRNA containing the 5 0-UTR intron sequence, were
observed (Fig. 4B, lane 2), indicating efficient splicing of the
5 0-UTR intron (intron 1) sequence. However, subsequent
PCR amplification of the RT-PCR products (lane 2) with
primer c and primer f did produce fragments of 395 and 455 bp,
which were expected for the presence of the unspliced 5 0-UTR
sequence, indicating that the intron 1 is mostly, but not
completely spliced (Fig. 4B, lane 10). This is in agreement
with the observation that no detectable amplified products was
obtained for RT-PCR using the same primer sets (Fig. 4B, lanes
3 and 4). In lane 10, an extra band of <490 bp corresponding to
the unknown band in lane 2 was also observed, suggesting that it
is a byproduct of nonspecific priming of primer f. With
combinations of primer c and splice variant-specific primers d
or e, 2b- and 1b-specific products (181 and 241 bp, respectively)
were also amplified (Fig. 4B, lanes 8 and 9). Sequence analysis
of these two products confirmed their identity with 2b and 1b,
respectively. The alternative splicings in the second intron
were estimated to take place in approximately half of the
hepsin transcripts, accounting for the similar abundance of
1.8 and 1.9-kb mRNA species [7]. Together, all four hepsin
forms (Fig. 1B) were generated from a single hepsin gene by
the alternative splicings in the 5 0-UTR and the second intron,
which independently take place from each other.
Promoter activity in HepG2 cells
To examine whether the 5 0-flanking sequence of the hepsin gene
up to nucleotide 2274 actually has promoter activity, we
generated two hepsin expression constructs (p-274HSN/FIXm1
and p-274HSNIn/FIXm1), which contain a hFIX minigene
reporter gene, FIXm1, linked to the 5 0-flanking sequence
with and without the 5 0-UTR intron (intron 1) sequence.
p-416FIXm1, which contains the hFIX promoter linked to
FIXm1, was used as a positive control [20]. HepG2 cells
transfected with p-416FIXm1 (1  106 cells) produced
50±60 ng of recombinant hFIX into the culture medium in 48 h
p-274HSN/FIXm1 produced hFIX at a 22% level of that by
p-416FIXm1 (Table 1). Inclusion of the 5 0-UTR intron
sequence in the expression vector (p-274HSNIn/FIXm1)
enhanced the hFIX expression level by < sevenfold over that
of p-274HSN/FIXm1 (Table 1). These results indicated that the
5 0-flanking sequence of the hepsin gene up to nucleotide 2274
has a strong promoter activity in HepG2 cells.
DISCUSSION
Hepsin was originally identified from human liver cDNA clones
in 1988 [1]. Since then, several important findings have been
made, strongly indicating it has potential physiological and
pathophysiological roles. However, its major physiological
function still remains unknown. We have determined its
complete contiguous nucleotide sequence and characterized
some important structural properties of the mouse hepsin gene.
The hepsin gene is <17 kb in size, and is composed of 12±14
exons depending on the combinations of the three alternative
splicings (Fig. 1B and Fig. 2). Interestingly, its transcription
initiation site (nucleotide +1), which is 636 bp 5 0-upstream to
the first Met codon, is in the middle of cytidine-rich region with
no specific TATA box present in the neighboring areas (Fig. 2).
Several known repetitive sequences in mouse genes including
B1, B2, and 5.5 units of Alu-like type III repetitive elements
have been found in introns (Fig. 2). These repeats, particularly
Alu-like type III repetitive repeats, which have five potential
Fig. 3. Transcription initiation site of the mouse hepsin gene. Primer
extension analysis was carried out with a radiolabeled 19-mer oligonucleo-
tide, which is designed complementary to the sequence nucleotides +77 to
+95. The reference sequence ladders were generated by sequencing reactions
with the same primer and corresponding DNA template. Lane 1, primer
extension products using total RNA treated with RNase A. Lane 2, same as
lane 1 except no [32P]-labeled primer was included. Lane 3, primer extension
products generated from mouse liver total RNA. The major transcription
initiation site is shown by an arrow.
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unique stem-loop structures, are of interest in relation to hepsin
gene regulation, and warrants further study. The exon/intron
organization pattern of the serine protease subunit belongs to the
complex type similar to those of plasminogen [35] and
prothrombin genes [36], but not to those of trypsin [37] and
factor IX [38]. Interestingly, an additional intron exists separat-
ing the last 12 amino acids of the C-terminal sequence into the
last exon, exon 14 (Fig. 2). The plasminogen and prothrombin
genes do not have any corresponding intron in the catalytic
subunits. Interestingly, however, the rat elastase gene has an
equivalent intron [39], while the overall exon/intron organi-
zations of the hepsin and elastase genes are dissimilar to each
other. The exon/intron organization pattern of the N-terminal
half of hepsin, where the hydrophobic sequence is contained, is
simmilar to those of membrane spanning domains of various
other membrane-associated protein genes [40,41].
An alternative splicing takes place in the 5 0-UTR of the
human hepsin transcripts as previously shown [1] (Fig. 1B,
2a,b). For mouse hepsin cDNAs, only spliced forms of this
intron have been observed to date [7]. The present studies, using
combinations of RT-PCR, and subsequent PCR demonstrate that
the intron in the 5 0-UTR is spliced in most, but not all of the
hepsin transcripts. Two mRNA species, 1.8 kb and 1.9 kb in
size, correspond to spliced and unspliced forms, respectively,
resulting from the two alternative splicing sequences in the
second intron [7]. Both spliced and unspliced forms are
produced in the liver at almost equal amounts as estimated
from the Northern blot analysis [7], which is further supported
by the present RT-PCR/PCR analyses. Importantly, two alter-
native splicings in the second intron generate a hepsin isoform
containing a unique stretch of 20 extra residues, DEEP-
GAHRGGSTCSRPQPGK, in frame in the cytosolic side. This
finding establishes that the single gene is responsible for
generating both forms of hepsin. This unique extra sequence is
predicted to have a highly twisted, irregular secondary structure
[42]. This isoform may be able to confer a distinct signal
transduction, not available to hepsin without this extra sequence,
thus endowing it with substantially different biological func-
tions. This and whether the similar alternative splicings take
place in tissues other than the liver have yet to be determined. As
shown by RT-PCR/PCR analyses, an alternative splicing in the
5 0-UTR obviously takes place independently from the other two
in the second intron (Fig. 4,A,B).
The basal hepsin promoter region (nucleotides 2274 to +59)
can confer strong expression activities, suggesting that the major
structural elements required for hepsin expression are contained
within this relatively small 5 0-flanking region. Elevation of the
transcriptional activity (< sevenfold) in the presence of an
intron when compared to levels in its absence is in agreement
with the similar observations for other genes [20]. A computer
search predicted several structural elements including SP1, AP2,
C/EBP, LF-A1, and E box present within the promoter region
(Fig. 2), suggesting that these elements may be in part
responsible for hepsin gene expression in the liver and other
tissues [3]. Preliminary footprinting analyses using the liver
nuclear extracts suggested apparent protein binding to the
predicted SP1 site (nucleotides 260 to 242), but not to other
sites (data not shown).
Hepsin has been suggested to have potential roles in
developement [6,7], both normal and cancer, cell growth [6],
and cell-surface initiation of blood coagulation [8]. Interestingly,
Table 1. Hepsin promoter activities with the Factor IX reporter gene.
Values represent mean hFIX levels ^ SD (n = 4). The hFIX level produced
by p-416FIXm1 is defined as 100%.
Constructs Relative factor IX level (%)
p-416FIXm1 100
p-274HSN/FIXm1 22 ̂ 4.2
p-274HSNIn/FIXm1 155 ^ 7.5
Fig. 4. PCR analysis of alternative splicings.
Panel A: schematic drawing of exons and the first
intron of hepsin with the relative locations of
primers (a±f ) used for RT-PCR and PCR. Intron 1
and exon III, which are generated by alternative
splicings, are also shown. The drawing does not
reflect the actual relative size of the exons. Panel
B: agarose gel electrophoresis of PCR products.
Total RNA (1 mg) from the mouse liver was
subjected to the initial RT-PCR (lane 2), followed
by subsequent PCR analyses with various primer
sets as described under Experimental procedures.
DNA ladder size markers are shown in lanes 1 and
11. Sizes (bp) of some DNA markers are shown on
the right side. Lanes 2±4, RT-PCR products
generated with different primer sets, a/f, c/d and
c/f, respectively. Lane 5, RT-PCR products of
mouse liver RNA treated with RNase A (a/f
primer set). Lanes 6±10, PCR products obtained
from the initial RT-PCR products generated by a/f
primer set (lane 2) as the template with primer
sets, b/d, b/e, c/d, c/e and c/f, respectively. As
confirmed by DNA sequencing, PCR amplified
fragments (462 and 402 bp in lane 2) are
generated by alternative splicings of intron 2
(Fig. 1B, 1a or 2a). Extra bands of an approximate
size of 490 bp seen in lanes 2 and 10 are likely
due to nonspecific priming of primer f.
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however, inactivation of the gene in mice results in an
approximate twofold increase in the level of alkaline phos-
phatase, but gives no other obvious abnormal effects (e.g. during
development) and animals are born virtually normal and survive
to adulthood [10]. This may be due to a possible presence of
redundant hepsin-like activities in mice. Furthermore, absence
of hepsin may have detrimental effects on the ageing process or
may affect pathological processes, such as cancer growth and
metastasis. Indeed, Tanimoto et al. [9] recently reported an
elevated hepsin expression in ovarian cancer, suggesting a
potentially important role in cancer. As several lines of
independent studies [3,6±9] strongly support the importance
of hepsin, further vigorous studies aiming to determine its
biological functions are warranted. Thus, availability of the
complete nucleotide sequence and establishment of key
functional characteristics of the hepsin gene will provide a
dependable foundation for such studies.
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